[Solved]: have i answered the question # Danny (the same…

have i answered the question # Danny (the same patient as in coursework 1) has a confirmed diagnosis of T2D. His glycaemic control is good and he has an HbA1c of 52mmol/mol. His renal and hepatic function is normal. You now need to address the other aspects of his diabetes management, with a particular focus on reducing Danny’s cardiovascular risk. His CVD risk score on QRisk is 13%. He continues to smoke and he drinks 10-20 units of alcohol per week but only at the weekends. His average day time BP reading, from a recent ambulatory BP trace, is 148/92 mm Hg. His total cholesterol is 5.2mmol/L and his HDL cholesterol is 1.0mmol/L. Consider the lifestyle and pharmacological interventions that should be implemented in order to reduce Danny’s cardiovascular risk. # Danny is a 48-year-old male with Type 2 Diabetes (T2D) His recent HbA1c blood results confirmed his blood glucose levels had increased from 46 mmol/mol to 52 mmol/mol over the past two years. Thus, indicates Danny’s glycemic levels are not optimised, although not ideal, he is not in the range for cardiovascular risk reduction. However, his levels are relatively controlled he presents with notable characteristics of cardiovascular risk factors that include QRisk score of 13% hypertension as his Blood pressure is 148/92 mm Hg, unfavourable lipid totals, cholesterol 5.2 mmol/L and HDL 1.0 mmol/L his smoking and moderate alcohol intake of 10 -20 units a week (Baker et al., 2021). This case study aims to evaluate Danny’s health status and the association between his diabetes and cardiovascular health and recommending interventions that focus ways to improve his lifestyle and pharmacological approaches in reducing his cardiovascular risk by following existing clinical guidelines. It will also cover the healthcare professionals’ perspective with regards to Danny’s self-care, which will involve his family, whilst employing behavioural approaches. T2D can be defined as insulin resistance and progressive pancreatic beta-cell function, Insulin resistance entails a decrease the effectiveness of insulin receptors, and glucose floods the blood plasma as cells cannot take it in. As insulin resistance continues, the pancreas tries to produce more insulin over time, the B-cells of the pancreas deteriorate, and production of insulin is reduced. (Eizirik et al., 2020). These two issues work together paving the way for the development of T2D, causing chronic hyperglycemia. Chronic hyperglycemia activates various biochemical processes, such as the formation of Advanced Glycation End Products (AGEs), which cause cellular dysfunction, inflammation, and oxidative Stress, promoting vascular complications (Papachristoforou et al., 2020). In T2D, these complications are especially atherosclerotic because the lining of the blood vessels are damaged. Endothelial dysfunction is a stage before atherosclerosis, it is driven by hyperglycemia due to inflammation and oxidative Stress that are upregulated while nitric oxide bioavailability is compromised thus reducing vasodilation (Theofilis et al., 2021). AGEs further aggravate this process, as they modify the structural and functional properties of the blood vessels that fuel inflammation. This dysfunction increases atherosclerosis by way of accumulating cholesterol and lipids aiding them to adhere to the inner sides of arteries to form plaques that hinder smooth blood flow. T2D comes with dyslipidaemia, a familiar lipid profile that leads to raised LDL and lowered HDL cholesterol that also advances atherosclerosis (Puig-Jové et al., 2022). Plaque depression causes the arteries to shrink, increasing the pressure on the heart and increasing the chances of developing hypertension, stroke, and CAD. Danny’s profile can illustrate these risks; having a BP of 148/92 mm Hg as he has an increased risk of cardiovascular events, as his QRisk of 13% predicts. His total cholesterol is 5.2 mmol/L, and low HDL is 1.0 mmol/L, reports a lipid profile which standard in dyslipidaemia in T2D. These levels play a role in the development of atherosclerosis, thereby increasing his risk for adverse cardiovascular events. Danny’s HbA1c of 52 mmol /mol indicates reasonably well-managed glycemia, although still far from the optimal level that would reduce CVD risk (Teo & Rafiq, 2021). That Danny is a smoker, and drinks alcohol once a week this increases the percentage of vascular burden and inflammation, along with other unfavourable changes, his clinical presentation and risk factors demand a complex intervention strategy to have better control of his cardiovascular risk factors and diabetes. In diabetes management, history-taking and a thorough clinical assessment are essential for creating an effective, personalised care plan, particularly for patients like Danny with cardiovascular risks. Understanding his smoki